Iranian Journal of Basic Medical Sciences، جلد ۲۰، شماره ۵، صفحات ۴۸۹-۴۹۶

عنوان فارسی
چکیده فارسی مقاله
کلیدواژه‌های فارسی مقاله

عنوان انگلیسی In vivo immunotherapy of lung cancer using cross-species reactive vascular endothelial growth factor nanobodies
چکیده انگلیسی مقاله Objective(s): Lung cancer is the main leading cause of cancer death worldwide. Angiogenesis is the main step in proliferation and spreading of tumor cells. Targeting vascular endothelial growth factor (VEGF) is an effective approach for inhibition of cancer angiogenesis. Nanobodies (NBs) are a novel class of antibodies derived from the camel. Unique characteristics of Nbs like their small size and good penetration to tumor tissues makes them promising tools in drug development.  Development of NBs targeting both human and mouse VEGF is required for understanding their in vivo functions.  Therefore, development of cross-species reactive anti-VEGF Nbs for immunotherapy of lung cancer was the main aim of the current study. Materials and Methods: Here we developed NBs from Camelus dromedarius library with high specificity and binding affinity to both human and mouse VEGF. In vitro and In vivo function of developed NB was evaluated on human endothelial cells and lung epithelial tumor cells (TC-1). Results: A nanobody showed the highest affinity to human and mouse VEGF and potently inhibited VEGF in the ELISA experiment. Anti-VEGF NBs significantly inhibited in vitro human endothelial cell migration through blockade of VEGF (P=0.045). Anti-VEGF NBs also significantly inhibited in vivo TC-1 growth in a dose-dependent manner (P=0.001) and resulted in higher survival rate in the nanobody treated group Conclusion: These findings demonstrate the potential of anti-VEGF NBsin tumor growth inhibition and are promising as novel cancer therapeutic candidate.
کلیدواژه‌های انگلیسی مقاله

نویسندگان مقاله vfatemeh کاظمی lomedasht v | vfatemeh kazemi lomedasht v
biotechnology research center, biotechnology department, venom amp; biotherapeutics molecules lab., pasteur institute of iran, tehran, iran

سازمان اصلی تایید شده: انستیتو پاستور ایران (Pasteur institute of iran)

کامران پوشنگ باقری | kamran pooshang bagheri
biotechnology research center, biotechnology department, venom amp; biotherapeutics molecules lab., pasteur institute of iran, tehran, iran

سازمان اصلی تایید شده: انستیتو پاستور ایران (Pasteur institute of iran)

مهدی حبیبی انبوهی | mahdi habibi anbouhi
national cell bank of iran, pasteur institute of iran, tehran, iran

سازمان اصلی تایید شده: انستیتو پاستور ایران (Pasteur institute of iran)

انسیه حاجی زاده صفر | ensiyeh hajizadeh safar
national cell bank of iran, pasteur institute of iran, tehran, iran

سازمان اصلی تایید شده: انستیتو پاستور ایران (Pasteur institute of iran)

دلاور شهباززاده | delavar shahbazzadeh
biotechnology research center, biotechnology department, venom amp; biotherapeutics molecules lab., pasteur institute of iran, tehran, iran

سازمان اصلی تایید شده: انستیتو پاستور ایران (Pasteur institute of iran)

حسن میرزاحسینی | hasan mirzahosseini
biotechnology research center, biotechnology department, venom amp; biotherapeutics molecules lab., pasteur institute of iran, tehran, iran

سازمان اصلی تایید شده: انستیتو پاستور ایران (Pasteur institute of iran)

مهدی بهدانی | mahdi behdani
biotechnology research center, biotechnology department, venom amp; biotherapeutics molecules lab., pasteur institute of iran, tehran, iran

سازمان اصلی تایید شده: انستیتو پاستور ایران (Pasteur institute of iran)


نشانی اینترنتی http://ijbms.mums.ac.ir/article_8672.html
فایل مقاله دریافت فایل مقاله
کد مقاله (doi)
زبان مقاله منتشر شده en
موضوعات مقاله منتشر شده
نوع مقاله منتشر شده Original Article
برگشت به: صفحه اول پایگاه   |   نسخه مرتبط   |   نشریه مرتبط   |   فهرست نشریات